Millennium Capital Advisors LLC Makes New $595,000 Investment in Stryker Corporation $SYK

Millennium Capital Advisors LLC bought a new position in shares of Stryker Corporation (NYSE:SYK) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 1,694 shares of the medical technology company’s stock, valued at approximately $595,000.

Several other hedge funds also recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in Stryker by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock worth $11,917,396,000 after buying an additional 133,892 shares during the period. Alliancebernstein L.P. lifted its position in shares of Stryker by 13.3% during the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after purchasing an additional 741,542 shares in the last quarter. Legal & General Group Plc lifted its position in shares of Stryker by 4.4% during the third quarter. Legal & General Group Plc now owns 2,303,290 shares of the medical technology company’s stock worth $851,457,000 after purchasing an additional 96,662 shares in the last quarter. Corient Private Wealth LLC lifted its position in shares of Stryker by 104.4% during the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock worth $887,525,000 after purchasing an additional 1,146,998 shares in the last quarter. Finally, Invesco Ltd. lifted its position in shares of Stryker by 4.5% during the third quarter. Invesco Ltd. now owns 1,864,918 shares of the medical technology company’s stock worth $689,404,000 after purchasing an additional 80,536 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on SYK shares. Wall Street Zen cut shares of Stryker from a “buy” rating to a “hold” rating in a research report on Saturday. Piper Sandler reissued an “overweight” rating on shares of Stryker in a research report on Tuesday, January 27th. The Goldman Sachs Group reissued a “neutral” rating and set a $361.00 price target on shares of Stryker in a research report on Friday, May 1st. BTIG Research reduced their price target on shares of Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Finally, William Blair reissued an “outperform” rating on shares of Stryker in a research report on Thursday, March 5th. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, Stryker presently has an average rating of “Moderate Buy” and a consensus target price of $395.48.

Stryker Stock Up 0.4%

Shares of NYSE:SYK opened at $306.74 on Friday. The firm’s 50 day moving average price is $329.68 and its 200 day moving average price is $351.73. The stock has a market cap of $117.59 billion, a price-to-earnings ratio of 35.50, a price-to-earnings-growth ratio of 1.93 and a beta of 0.80. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm’s revenue was up 2.6% compared to the same quarter last year. During the same period last year, the business earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities research analysts predict that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio (DPR) is 40.74%.

Insiders Place Their Bets

In related news, VP M Kathryn Fink sold 3,500 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.45, for a total value of $992,075.00. Following the sale, the vice president owned 177 shares of the company’s stock, valued at $50,170.65. This trade represents a 95.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.60% of the stock is currently owned by company insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.